Long-term treatment with Nucala (mepolizumab) reduces disease activity and helps to prevent progressive organ damage in people with eosinophilic granulomatosis…
Articles by Patricia Inacio, PhD
Plasma exchange added to standard immunosuppressive treatments helps improve early kidney function in people with ANCA-associated vasculitis (AAV) who…
High blood levels of the syndecan-1 protein, known to promote the survival of antibody-producing B cells, may help identify…
Using data from the largest ANCA-associated vasculitis (AAV) patient database compiled to date, researchers identified five new subgroups that…
Treatment with the asthma medication montelukast may trigger eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated…
Melodia Therapeutics has acquired the exclusive rights to develop, manufacture, and commercialize MDI-0151, a candidate therapy for hard-to-treat…
Sinonasal manifestations — those encompassing the nose and the paranasal sinuses, or the air-filled cavities around the nose — in…
AstraZeneca’s Fasenra (benralizumab), which is approved for a rare type of asthma, led to clinical remission in up to…
A Phase 1 clinical trial evaluating the safety and preliminary efficacy of Sana Biotechnology’s candidate CAR T-cell therapy SC291…
Lower blood counts of platelets — tiny cell fragments involved in blood clotting — at the time that ANCA-associated…